Cargando…
Nasal powders of thalidomide for local treatment of nose bleeding in persons affected by hereditary hemorrhagic telangiectasia
In this work nasal powder formulations of thalidomide were designed and studied to be used by persons affected by hereditary hemorrhagic telangiectasia as a complementary anti-epistaxis therapy, with the goal of sustaining the effect obtained with thalidomide oral treatment after its discontinuation...
Autores principales: | Colombo, G., Bortolotti, F., Chiapponi, V., Buttini, F., Sonvico, F., Invernizzi, R., Quaglia, F., Danesino, C., Pagella, F., Russo, P., Bettini, R., Colombo, P., Rossi, A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier/North-Holland Biomedical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120990/ https://www.ncbi.nlm.nih.gov/pubmed/27863666 http://dx.doi.org/10.1016/j.ijpharm.2016.07.002 |
Ejemplares similares
-
Safety of thalidomide and bevacizumab in patients with hereditary hemorrhagic telangiectasia
por: Buscarini, Elisabetta, et al.
Publicado: (2019) -
Recent Patents on Nasal Vaccines Containing Nanoadjuvants
por: Candela, Francesco, et al.
Publicado: (2022) -
Hereditary Hemorrhagic Telangiectasia in Pediatric Age: Focus on Genetics and Diagnosis
por: Danesino, Cesare, et al.
Publicado: (2023) -
Surface-Modified Nanocarriers for Nose-to-Brain Delivery: From Bioadhesion to Targeting
por: Sonvico, Fabio, et al.
Publicado: (2018) -
Thalidomide for the Management of Bleeding Episodes in Patients with Hereditary Hemorrhagic Telangiectasia: Effects on Epistaxis Severity Score and Quality of Life
por: Baysal, Mehmet, et al.
Publicado: (2019)